scRNA-seq data showed that secukinumab is superior to glucocorticoids and methotrexate in ameliorating hypoxic conditions in psoriasis, as evidenced by the downregulation of HIF-1α expression [Figs. 8(g)–8(i)]. Here, HIF1A is linked to psoriasis.